[Research progress of molecular imprinting technology in the field of disease diagnosis and therapy]. [PDF]
Se PuZhu R, Cai GP, Zheng HJ, Jia Q.
europepmc +1 more source
, 2010 本发明针对化石资源的日益短缺，而生物质的特性和利用方式与化石资源有很大的相似性且绿色环保可再生的特点，提出了一种微藻催化裂解制取低碳烯烃的方法。其步骤是，以微藻为原料，在催化剂作用下，将微藻直接催化裂解制取低碳烯烃；催化裂解反应条件：温度400～750℃；催化剂与微藻干基重量比1～70∶1；催化剂为沸石分子筛、氧化铝、二氧化硅、硅藻土、高岭土、酸性白土中的一种或几种多孔材料的混合物 ...
刘中民 +4 more
core
[Determination of ergot alkaloids toxins in forage grass by ultra performance liquid chromatography-tandem mass spectrometry coupled with solid-phase supported liquid-liquid extraction]. [PDF]
Se PuRen CX +5 more
europepmc +1 more source
, 1988 本文比较研究了洪湖三种基质上的周丛硅藻群落的种类组成、群落结构及其演替。三种基质分别是聚草（Myriophyllum spicatur）、黄丝草（Potamogeton maackianus）和人工放置的载玻片。在1987.7.到12月的时间内，曾出现过的优势种有Epitheniia zerbra、Cocconeis placentula var. euglypta, Achnanthes minutisstma, Cymbella spp.
翁立江
core
, 2009 采用活塞取样器采集了月湖湖中央2处钻孔沉积物,分析了其中硅藻种类与密度的垂直变化,同时采用210Pb/137Cs推测沉积物的沉积速率,并进行了总有机质、生物硅含量分析,以了解月湖各个不同年代的水质变化。结果表明,2个柱状沉积物中硅藻的优势属为:小环藻属、直链藻属、舟形藻属、Cyclostephanos属。Z-1钻孔优势种为:梅尼小环藻、颗粒直链藻、Navicula porifera、Cyclostephanos tholifomis。Z-2钻孔中优势种为:梅尼小环藻、颗粒直链藻、舟形藻 ...
徐栋 +5 more
core
[Determination of 17 bisphenol compounds in human urine by solid supported liquid-liquid extraction-ultra-high performance liquid chromatography-tandem mass spectrometry]. [PDF]
Se PuJin Y +6 more
europepmc +1 more source
[Research progress on sample pretreatment technology for the analysis of new pollutants in food using composite covalent organic framework materials]. [PDF]
Se PuSun ZY, Yuan GN, Niu YY, Ma JP.
europepmc +1 more source
[Phenotype and gene analysis of a hereditary coagulation factor Ⅻ deficiency]. [PDF]
Zhonghua Xue Ye Xue Za Zhi, 2018 Li SS +9 more
europepmc +1 more source
[New Advances in the Application of Bacterial Cellulose Composite Materials in the Field of Bone Tissue Engineering]. [PDF]
Sichuan Da Xue Xue Bao Yi Xue BanLuo C, Zhang L, Ran L, You X, Huang S.
europepmc +1 more source
[3-O-β-chacotriosyl glycyrrhetinic acid derivatives as potential small-molecule SARS-CoV-2 fusion inhibitors against SARS-CoV-2 entry into host cells]. [PDF]
Nan Fang Yi Ke Da Xue Xue BaoWan X, Hong C, Wang J, Song G, Liu S.
europepmc +1 more source